US › Healthcare

Innoviva Inc (INVA)

US · Healthcare · Biotechnology

$20.86+0.43%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$98.0M
Revenue YoY
+10.6%
Net profit
$186.6M
Profit YoY
+500.6%
EPS
$0.47
EPS estimate
$0.43
Net margin
190.4%

EPS came in at 0.47 against a street estimate of 0.43 — a beat of 9.3%.

Key statistics

Market cap
$1.55B
P/E
3.4
Forward P/E
10.7
P/B
1.15
Book value
$18.18
EPS (TTM)
$6.19
52-week high
$25.14
52-week low
$16.52
50-day MA
$22.18
200-day MA
$21.52
Beta
0.34

Analyst view

Analysts rate Innoviva Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $35.50.

Shareholding

Insiders
0.99%
Institutions
108.08%

Largest institutional holders

FundStake
BlackRock Inc15.32%
Vanguard Group Inc10.73%
Dimensional Fund Advisors, Inc.6.01%
Vanguard Portfolio Management, LLC5.72%
Renaissance Technologies Corp5.49%
Vanguard Capital Management, LLC4.26%
State Street Corp4.15%
Millennium Management LLC3.09%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Innoviva Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.